

Studien zu Medizinalcannabis nach Indikation

Inhalt

Hier finden Sie eine Auswahl von Studien zu verschiedenen Symptomen und Krankheiten, die auch bei der Antragstellung zur Kostenübernahme durch die Krankenkassen einbezogen werden können.

Alle Studien sind mit dem Text verlinkt. Somit können Sie die Studien im digitalen Dokument sofort per Mausklick finden.

Brechreiz und Übelkeit

- Meiri, E., Jhangiani, H., Vredenburg, J. J., Barbato, L. M., Carter, F. J., Yang, H. M., & Baranowski, V. (2007). Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. *Current medical research and opinion*, 23(3), 533–543. <https://doi.org/10.1185/030079907x167525>
- Layeeque, R., Siegel, E., Kass, R., Henry-Tillman, R. S., Colvert, M., Mancino, A., & Klimberg, V. S. (2006). Prevention of nausea and vomiting following breast surgery. *American journal of surgery*, 191(6), 767–772. <https://doi.org/10.1016/j.amjsurg.2005.07.040>
- Tramèr, M. R., Carroll, D., Campbell, F. A., Reynolds, D. J., Moore, R. A., & McQuay, H. J. (2001). Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. *BMJ (Clinical research ed.)*, 323(7303), 16–21. <https://doi.org/10.1136/bmj.323.7303.16>
- Gonzalez-Rosales, F., & Walsh, D. (1997). Intractable nausea and vomiting due to gastrointestinal mucosal metastases relieved by tetrahydrocannabinol (dronabinol). *Journal of pain and symptom management*, 14(5), 311–314. [https://doi.org/10.1016/S0885-3924\(97\)00229-7](https://doi.org/10.1016/S0885-3924(97)00229-7)
- Grimison, P., Mersiades, A., Kirby, A., Lintzeris, N., Morton, R., Haber, P., Olver, I., Walsh, A., McGregor, I., Cheung, Y., Tognela, A., Hahn, C., Briscoe, K., Aghmesheh, M., Fox, P., Abdi, E., Clarke, S., Della-Fiorentina, S., Shannon, J., Gedye, C., ... Stockler, M. (2020). Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. *Annals of oncology : official journal of the European Society for Medical Oncology*, 31(11), 1553–1560. <https://doi.org/10.1016/j.annonc.2020.07.020>

Entzündung

- Petrosino, S., Verde, R., Vaia, M., Allarà, M., Iuvone, T., & Di Marzo, V. (2018). Cannabidiol and Allergic Contact Dermatitis. *Journal of Pharmacology and Experimental Therapeutics*, 365(3), 652–663. <https://doi.org/10.1124/jpet.117.244368>
- Esposito, G., Filippis, D.D., Cirillo, C., Iuvone, T., Capoccia, E., Scuderi, C., Steardo, A., Cuomo, R. and Steardo, L. (2013), Cannabidiol in Inflammatory Bowel Diseases: A Brief Overview. *Phytother. Res.*, 27: 633–636. <https://doi.org/10.1002/ptr.4781>
- Atalay, S., Jarocka-Karpowicz, I., & Skrzydlewska, E. (2019). Antioxidative and Anti-Inflammatory Properties of Cannabidiol. *Antioxidants*, 9(1), 21. [doi:10.3390/antiox9010021](https://doi.org/10.3390/antiox9010021)
- Nichols, J. M., & Kaplan, B. (2020). Immune Responses Regulated by Cannabidiol. *Cannabis and cannabinoid research*, 5(1), 12–31. <https://doi.org/10.1089/can.2018.0073>

Epilepsie

- Hussain, S. A., Zhou, R., Jacobson, C., Weng, J., Cheng, E., Lay, J., Hung, P., Lerner, J. T., & Sankar, R. (2015). Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome. *Epilepsy & behavior : E&B*, 47, 138-141. <https://doi.org/10.1016/j.yebeh.2015.04.009>
- Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., Miller, I., Flamini, R., Wilfong, A., Filloux, F., Wong, M., Tilton, N., Bruno, P., Bluvstein, J., Hedlund, J., Kamens, R., Maclean, J., Nangia, S., Singhal, N. S., Wilson, C. A., ... Cilio, M. R. (2016). Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. *The Lancet. Neurology*, 15(3), 270-278. [https://doi.org/10.1016/S1474-4422\(15\)00379-8](https://doi.org/10.1016/S1474-4422(15)00379-8)
- Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., Scheffer, I. E., Thiele, E. A., Wright, S., & Cannabidiol in Dravet Syndrome Study Group (2017). Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. *The New England journal of medicine*, 376(21), 2011-2020. <https://doi.org/10.1056/NEJMoa1611618>
- Gaston, T. E., & Friedman, D. (2017). Pharmacology of cannabinoids in the treatment of epilepsy. *Epilepsy & behavior : E&B*, 70(Pt B), 313-318. <https://doi.org/10.1016/j.yebeh.2016.11.016>
- Russo E. B. (2017). Cannabis and epilepsy: An ancient treatment returns to the fore. *Epilepsy & behavior : E&B*, 70(Pt B), 292-297. <https://doi.org/10.1016/j.yebeh.2016.09.040>
- dos Santos, R. G., Hallak, J. E., Leite, J. P., Zuardi, A. W., & Crippa, J. A. (2015). Phytocannabinoids and epilepsy. *Journal of clinical pharmacy and therapeutics*, 40(2), 135-143. <https://doi.org/10.1111/jcpt.12235>
- Arzimanoglou, A., Brandl, U., Cross, J. H., Gil-Nagel, A., Lagae, L., Landmark, C. J., Specchio, N., Nabbout, R., Thiele, E. A., Gubbay, O., The Cannabinoids International Experts Panel, & Collaborators (2020). Epilepsy and cannabidiol: a guide to treatment. *Epileptic disorders : international epilepsy journal with videotape*, 22(1), 1-14. <https://doi.org/10.1684/epd.2020.1141>

Hauterkrankungen

- Sangiovanni, E, Fumagalli, M, Pacchetti, B, et al. Cannabis sativa L. extract and cannabidiol inhibit in vitro mediators of skin inflammation and wound injury. *Phytotherapy Research*. 2019; 33: 2083– 2093. <https://doi.org/10.1002/ptr.6400>
- Atalay, S., Gegotek, A., Wronski, A., Domigues, P., & Skrzydlewska, E. (2021). Therapeutic application of cannabidiol on UVA and UVB irradiated rat skin. A proteomic study. *Journal of Pharmaceutical and Biomedical Analysis*, 192, 113656. <https://doi.org/10.1016/j.jpba.2020.113656>
- Jhavar, N., Schoenberg, E., Wang, J. V., & Saedi, N. (2019). The growing trend of cannabidiol in skincare products. *Clinics in Dermatology*, 37(3), 279–281. <https://doi.org/10.1016/j.clindermatol.2018.11.002>

HIV/Aids

- DeJesus, E., Rodwick, B. M., Bowers, D., Cohen, C. J., & Pearce, D. (2007). Use of Dronabinol Improves Appetite and Reverses Weight Loss in HIV/AIDS-Infected Patients. *Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)*, 6(2), 95–100.
- Costiniuk, C. T., & Jenabian, M. A. (2019). Cannabinoids and inflammation: implications for people living with HIV. *AIDS (London, England)*, 33(15), 2273–2288. <https://doi.org/10.1097/QAD.0000000000002345>

Spastik

- Petro, D. J., & Ellenberger, C., Jr (1981). Treatment of human spasticity with delta 9-tetrahydrocannabinol. *Journal of clinical pharmacology*, 21(S1), 413S–416S. <https://doi.org/10.1002/j.1552-4604.1981.tb02621.x>
- Ungerleider, J. T., Andyrsiak, T., Fairbanks, L., Ellison, G. W., & Myers, L. W. (1987). Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. *Advances in alcohol & substance abuse*, 7(1), 39–50. https://doi.org/10.1300/j251v07n01_04
- Maurer, M., Henn, V., Dittrich, A., & Hofmann, A. (1990). Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. *European archives of psychiatry and clinical neuroscience*, 240(1), 1–4. <https://doi.org/10.1007/BF02190083>
- Brenneisen, R., Egli, A., Elsohly, M. A., Henn, V., & Spiess, Y. (1996). The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. *International journal of clinical pharmacology and therapeutics*, 34(10), 446–452.

Krebs

- McAllister, S. D., Christian, R. T., Horowitz, M. P., Garcia, A., & Desprez, P. Y. (2007). Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. *Molecular Cancer Therapeutics*, 6(11), 2921-2927. <https://doi.org/10.1158/1535-7163.mct-07-0371>
- Aviello, G., Romano, B., Borrelli, F., Capasso, R., Gallo, L., Piscitelli, F., di Marzo, V., & Izzo, A. A. (2012). Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. *Journal of Molecular Medicine*, 90(8), 925-934. <https://doi.org/10.1007/s00109-011-0856-x>
- Sultan, A. S., Marie, M. A., & Sheweita, S. A. (2018). Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines. *The Breast*, 41, 34-41. <https://doi.org/10.1016/j.breast.2018.06.009>
- Kenyon, J., Liu, W., & Dalgeish, A. (2018). Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol. *Anticancer Research*, 38(10), 5831-5835. <https://doi.org/10.21873/anticancer.12924>
- Zutt, M., Hänssle, H., Emmert, S., Neumann, C., & Kretschmer, L. (2006). Dronabinol zur supportiven Therapie metastasierter maligner Melanome mit Lebermetastasen [Dronabinol for supportive therapy in patients with malignant melanoma and liver metastases]. *Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete*, 57(5), 423-427. <https://doi.org/10.1007/s00105-005-1063-x>
- Osei-Hyiaman D. (2007). Endocannabinoid system in cancer cachexia. *Current opinion in clinical nutrition and metabolic care*, 10(4), 443-448. <https://doi.org/10.1097/MCO.0b013e3281900ecc>
- Gorter R. W. (1999). Cancer cachexia and cannabinoids. *Forschende Komplementarmedizin*, 6 Suppl 3, 21-22. <https://doi.org/10.1159/000057152>

Schmerzen

- Costa, B., Trovato, A. E., Comelli, F., Giagnoni, G., & Colleoni, M. (2007). The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. *European Journal of Pharmacology*, 556(1-3), 75-83. <https://doi.org/10.1016/j.ejphar.2006.11.006>
- Hammell, D., Zhang, L., Ma, F., Abshire, S., McIlwrath, S., Stinchcomb, A., & Westlund, K. (2015). Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. *European Journal of Pain*, 20(6), 936-948. <https://doi.org/10.1002/ejp.818>
- Boyaji, S., Merkow, J., Elman, R. N. M., Kaye, A. D., Yong, R. J., & Urman, R. D. (2020). The Role of Cannabidiol (CBD) in Chronic Pain Management: An Assessment of Current Evidence. *Current Pain and Headache Reports*, 24(2). <https://doi.org/10.1007/s11916-020-0835-4>
- Lynch, M. E., & Campbell, F. (2011). Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. *British journal of clinical pharmacology*, 72(5), 735-744. <https://doi.org/10.1111/j.1365-2125.2011.03970.x>
- Bestard, J. A., & Toth, C. C. (2011). An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy. *Pain practice : the official journal of World Institute of Pain*, 11(4), 353-368. <https://doi.org/10.1111/j.1533-2500.2010.00427.x>
- Weber, J., Schley, M., Casutt, M., Gerber, H., Schuepfer, G., Rukwied, R., Schleinker, W., Ueberall, M., & Konrad, C. (2009). Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey. *Anesthesiology research and practice*, 2009, 827290. <https://doi.org/10.1155/2009/827290>
- Haroutiunian, S., Rosen, G., Shouval, R., & Davidson, E. (2008). Open-label, add-on study of tetrahydrocannabinol for chronic nonmalignant pain. *Journal of pain & palliative care pharmacotherapy*, 22(3), 213-217. <https://doi.org/10.1080/15360280802251215>
- Narang, S., Gibson, D., Wasan, A. D., Ross, E. L., Michna, E., Nedeljkovic, S. S., & Jamison, R. N. (2008). Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. *The journal of pain*, 9(3), 254-264. <https://doi.org/10.1016/j.jpain.2007.10.018>
- Wissel, J., Haydn, T., Müller, J., Brenneis, C., Berger, T., Poewe, W., & Schelosky, L. D. (2006). Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial. *Journal of neurology*, 253(10), 1337-1341. <https://doi.org/10.1007/s00415-006-0218-8>

Sucht, Depression, andere psychische Erkrankungen

- Batalla, A., Janssen, H., Gangadin, S. S., & Bossong, M. G. (2019). The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review. *Journal of Clinical Medicine*, 8(7), 1058. <https://doi.org/10.3390/jcm8071058>
- Appiah-Kusi, E., Petros, N., Wilson, R., Colizzi, M., Bossong, M. G., Valmaggia, L., Mondelli, V., McGuire, P., & Bhattacharyya, S. (2020). Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis. *Psychopharmacology*, 237(4), 1121-1130. <https://doi.org/10.1007/s00213-019-05442-6>
- Schubart, C., Sommer, I., Fusar-Poli, P., de Witte, L., Kahn, R., & Boks, M. (2014). Cannabidiol as a potential treatment for psychosis. *European Neuropsychopharmacology*, 24(1), 51-64. <https://doi.org/10.1016/j.euroneuro.2013.11.002>
- Schier, A., Ribeiro, N., Coutinho, D., Machado, S., Arias-Carrion, O., Crippa, J., Zuardi, A., Nardi, A., & Silva, A. (2014). Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa. *CNS & Neurological Disorders - Drug Targets*, 13(6), 953-960. <https://doi.org/10.2174/1871527313666140612114838>
- Shbiro, L., Hen-Shoval, D., Hazut, N., Rapps, K., Dar, S., Zalsman, G., Mechoulam, R., Weller, A., & Shoval, G. (2019). Effects of cannabidiol in males and females in two different rat models of depression. *Physiology & Behavior*, 201, 59-63. <https://doi.org/10.1016/j.physbeh.2018.12.019>